<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[exubera Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/exubera.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to exubera]]></description>
	<s:counts start="0" returned="5" found="5" />
	<language>en-us</language>
	<item>
		<title><![CDATA[In Exubera's Shadow: Generex Bets Oral Spray Is Next Big Thing for Diabetics]]></title>
		<link><![CDATA[http://www.bnet.com/5208-14054-0.html?forumID=1&threadID=3751&messageID=17675&start=0]]></link>
		<description><![CDATA[In Exubera's Shadow: Generex Bets Oral Spray Is Next Big Thing for DiabeticsRE: In Exubera's Shadow: Generex Bets Oral Spray Is Next Big Thing for Diabetics..."What do you think?"...well, right now I think you are either one dumb, gullible SOB or else you're on GNBT's payroll...absorption of oralyn's insulin is...]]></description>
		<s:doctype><![CDATA[Discussion threads]]></s:doctype>
		<pubDate>Wed, 01 Oct 2008 16:20:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational accounting]]></category>
		<category domain="http://resources.bnet.com/topic/exubera.html"><![CDATA[Exubera]]></category>
		<category domain="http://resources.bnet.com/topic/diabetic.html"><![CDATA[Diabetic]]></category>
		<category domain="http://resources.bnet.com/topic/generex+bets+oral+spray.html"><![CDATA[Generex Bets Oral Spray]]></category>
		<category domain="http://resources.bnet.com/topic/insulin.html"><![CDATA[insulin]]></category>
		<category domain="http://resources.bnet.com/topic/absorption.html"><![CDATA[absorption]]></category>
	</item>
	<item>
		<title><![CDATA[In Exubera's Shadow: Generex Bets Oral Spray Is Next Big Thing for Diabetics]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000242/in-exuberas-shadow-generex-bets-oral-spray-is-the-new-big-thing-for-diabetics/]]></link>
		<description><![CDATA[As companies bail out of the inhaled insulin business -- most recently Pfizer, which lost $2.8 billion before throwing Exubera overboard -- one small firm believes there is an alternative to pills, injections and inhalers.    Generex, a Worcester, Mass.-based company, believes there's an opportunity for insulin delivery...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Fri, 26 Sep 2008 14:02:49 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/lung.html"><![CDATA[Lung]]></category>
		<category domain="http://resources.bnet.com/topic/puff.html"><![CDATA[Puff]]></category>
		<category domain="http://resources.bnet.com/topic/molecule.html"><![CDATA[Molecule]]></category>
		<category domain="http://resources.bnet.com/topic/exubera.html"><![CDATA[Exubera]]></category>
		<category domain="http://resources.bnet.com/topic/oral-lyn.html"><![CDATA[Oral-Lyn]]></category>
		<category domain="http://resources.bnet.com/topic/a1c.html"><![CDATA[A1C]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[Security]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Sanofi-Aventis profits rise 53.6 percent on Exubera licence sale]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmafp/is_200605/ai_n16377425]]></link>
		<description><![CDATA[PARIS AFP &#8212; Pharmaceutical group Sanofi-Aventis has reported that first-quarter net profit had surged by 53.6 percent with a big injection from the sale of the patent for diabetes treatment Exubera to US group Pfizer.  Net profit amounted to 2.173 billion euros (2.76 billion dollars), far above the figure...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 05 May 2006 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agence+france-presse.html"><![CDATA[Agence France-Presse]]></category>
		<category domain="http://resources.bnet.com/topic/exubera.html"><![CDATA[Exubera]]></category>
		<category domain="http://resources.bnet.com/topic/patent.html"><![CDATA[patent]]></category>
		<category domain="http://resources.bnet.com/topic/sanofi-aventis.html"><![CDATA[Sanofi-Aventis]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Mannkind entering fray over inhaled insulin market]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb274/is_13_10/ai_n29194318]]></link>
		<description><![CDATA[MannKind Corp. marched into the American Diabetes Association's 65th annual Scientific Sessions last week looking a little bit like an underdog.  But despite the fact that rival pharmaceutical companies are likely to beat MannKind to the market with competing insulin delivery products, the Valencia-based company has plenty of reasons...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 20 Jun 2005 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/american+diabetes+association.html"><![CDATA[American Diabetes Association]]></category>
		<category domain="http://resources.bnet.com/topic/exubera.html"><![CDATA[Exubera]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/mannkind+corp..html"><![CDATA[MannKind Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/technosphere.html"><![CDATA[Technosphere]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MNKD</category>
		<category domain="tickers">MNKD</category>
	</item>
	<item>
		<title><![CDATA[US FDA accepts diabetes drug application by Sanofi-Aventis, Pfizer]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmafp/is_200503/ai_n13269266]]></link>
		<description><![CDATA[PARIS AFP &#8212; The US Food and Drug Administration has accepted a new drug application by French pharmaceutical group Sanofi-Aventis and Pfizer of the United States for Exubera, a dry powder form of insulin that is inhaled into the lungs prior to eating, the companies said.  The companies want...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 02 Mar 2005 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/agence+france-presse.html"><![CDATA[Agence France-Presse]]></category>
		<category domain="http://resources.bnet.com/topic/exubera.html"><![CDATA[Exubera]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sanofi-aventis.html"><![CDATA[Sanofi-Aventis]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">PFE</category>
	</item>
</channel>
</rss>
